Usage of different lots of RLDs in multistage adaptive studies [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2018-09-20 12:19 (860 d 02:10 ago) – Posting: # 19294
Views: 1,435

Hi manusyriac,

» Can we use different lots of RLDS in multistage studies as the study design requires more than 2 years of shelf-life for RLDs. If it is possible please help me to find any relevant regulatory guidance for the same.

Without being absolutely sure I think this would be ok with most EU authorities for the reasons you state. Less convinced about how HC or FDA or PMDA would see it.
Note that in your case batch and stage will have the same meaning for the product(s) in question.

Pass or fail!
ElMaestro

Complete thread:

Activity
 Admin contact
21,316 posts in 4,446 threads, 1,489 registered users;
online 20 (2 registered, 18 guests [including 2 identified bots]).
Forum time: Wednesday 13:30 CET (Europe/Vienna)

Nothing fails like success because you do not learn anything from it.
The only thing we ever learn from is failure.
Success only confirms our superstitions.    Kenneth E. Boulding

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5